Support for Small Business Innovation Research (SBIR) to Develop New Methods and Technologies for Assessment of Risk and for Early Diagnosis and Prognosis of Type 1 Diabetes (R43/R44 Clinical Trial Not Allowed)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) for funding to perform research leading to the development of innovative technologies that may advance progress for early detection and assessment of individuals at risk and for early diagnosis, prognosis and follow-up of type 1 diabetes (T1D) to avoid acute complications at diagnosis and to allow earlier interventions to prevent and/or delay clinical manifestations and long term complications of the disease.


  • Letter of Intent Due Date(s): January 17, 2022 and September 07, 2022

  • Application Due Date(s): February 17, 2022 and October 7, 2022

RFA-DK-21-021 Expiration Date October 08, 2022

Agency Website

Eligibility Requirements

Only United States small business concerns (SBCs) are eligible to submit applications for this opportunity.

Amount Description

Budgets up to $300,000 total costs per project for Phase I and up to $2,000,000 total costs per project for Phase II may be requested.


Funding Type





Engineering and Physical Sciences
Medical - Clinical Science
Medical - Translational

External Deadline

October 7, 2022